Technical Analysis for LQDA - Liquidia Technologies, Inc.

Grade Last Price % Change Price Change
F 10.12 -0.39% -0.04
LQDA closed down 0.39 percent on Wednesday, November 20, 2024, on 86 percent of normal volume.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Multiple of Ten Bullish Other 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish -0.39%
Stochastic Buy Signal Bullish -0.39%
Lower Bollinger Band Walk Weakness -0.39%
Multiple of Ten Bullish Other -0.39%
Outside Day Range Expansion -0.39%
Lower Bollinger Band Touch Weakness -0.39%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 21 hours ago
Up 1% about 21 hours ago
Rose Above Previous Day's High about 22 hours ago
Down 1% about 22 hours ago
Rose Above Previous Day's High 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Liquidia Technologies, Inc. Description

Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Pharmaceutical Pain Medication Hypertension Opioids Clinical Trial Uniform Pulmonary Arterial Hypertension Bupivacaine Inhaler Treprostinil

Is LQDA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.99
52 Week Low 6.69
Average Volume 885,674
200-Day Moving Average 12.32
50-Day Moving Average 10.55
20-Day Moving Average 10.60
10-Day Moving Average 10.35
Average True Range 0.42
RSI (14) 41.18
ADX 20.13
+DI 19.52
-DI 21.28
Chandelier Exit (Long, 3 ATRs) 10.21
Chandelier Exit (Short, 3 ATRs) 10.98
Upper Bollinger Bands 11.43
Lower Bollinger Band 9.76
Percent B (%b) 0.21
BandWidth 15.74
MACD Line -0.20
MACD Signal Line -0.10
MACD Histogram -0.0937
Fundamentals Value
Market Cap 767.22 Million
Num Shares 75.8 Million
EPS -0.88
Price-to-Earnings (P/E) Ratio -11.50
Price-to-Sales 61.30
Price-to-Book 23.37
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.65
Resistance 3 (R3) 10.65 10.48 10.56
Resistance 2 (R2) 10.48 10.35 10.48 10.53
Resistance 1 (R1) 10.30 10.26 10.22 10.30 10.50
Pivot Point 10.13 10.13 10.09 10.13 10.13
Support 1 (S1) 9.95 10.00 9.87 9.95 9.74
Support 2 (S2) 9.78 9.91 9.78 9.71
Support 3 (S3) 9.60 9.78 9.68
Support 4 (S4) 9.60